Title
Category
Credits
Event date
Cost
Remission and Treatment Augmentation of Depression in the United States
  • Depression
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
Determinants of Hepatitis C Virus Prevalence in People With Serious Mental Illness: A Systematic Review and Meta-Analysis
  • Hepatitis
  • Medical Conditions
  • Neuropsychiatric Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Increased screening for hepatitis C virus among people with serious mental illness is key to achieving global eradication of the virus.
Identification and Management of Night Eating Syndrome in the Adolescent and Young Adult Population
  • Eating Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Night eating syndrome is a condition that requires early identification and management, especially among adolescents who develop symptoms during the transition into adulthood.
Measurement-Based Care for Psychotic Disorders in the Veterans Health Administration: Current Practices and Future Directions
  • Psychotic Disorders
  • Veterans and Military Issues
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Measurement-based care (MBC) can improve patient outcomes, but data on its use in psychosis are sparse. This study examined the use of patient-reported outcome measures in veterans with psychosis to identify candidate measures for psychosis-related MBC.
An Update on the Future of Wilson Disease Management
  • Wilson Disease
  • Genetics
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.
Recent Advances in Screening for Mild Cognitive Impairment and Alzheimer Disease
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
Diagnosing and Treating Alzheimer Disease During the Early Stage
  • Alzheimer Disease
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Optimizing Mental Health for Women: Recognizing and Treating Mood Disorders Throughout the Lifespan
  • Mood Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Program IntroductionMood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.Learning ObjectivesAfter completing this educational activity, you should be able to: